|
Mar 25
|
Dyne Therapeutics Announces CEO Transition
|
|
Mar 13
|
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
|
|
Mar 7
|
Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ...
|
|
Mar 5
|
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|
|
Feb 14
|
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
|
|
Jan 14
|
Institutional owners may ignore Dyne Therapeutics, Inc.'s (NASDAQ:DYN) recent US$56m market cap decline as longer-term profits stay in the green
|
|
Jan 11
|
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
|
|
Jan 3
|
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
|
|
Jan 2
|
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
|
|
Sep 28
|
Dyne Therapeutics to Present at October Investor Conferences
|